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ABSTRACT b2-Microglobulin-deficient (b2m2) mice
generate a CD41 major histocompatibility complex class
II-restricted cytotoxic T-lymphocyte (CTL) response follow-
ing infection with lymphocytic choriomeningitis (LCM) virus
(LCMV). We have determined the cytotoxic mechanism used
by these CD41 CTLs and have examined the role of this
cytotoxic activity in pathogenesis of LCM disease in b2m2
mice. Lysis of LCMV-infected target cells by CTLs from b2m2
mice is inhibited by addition of soluble Fas-Ig fusion proteins
or by pretreatment of the CTLs with the protein synthesis
inhibitor emetine. In addition, LCMV-infected cell lines that
are resistant to anti-Fas-induced apoptosis are refractory to
lysis by these virus-specific CD41 CTLs. These data indicate
that LCMV-specific CD41 CTLs from b2m2 mice use a
Fas-dependent lytic mechanism. Intracranial (i.c.) infection of
b2m2 mice with LCMV results in loss of body weight. Fas-
deficient b2m2.lpr mice develop a similar wasting disease
following i.c. infection. This suggests that Fas-dependent
cytotoxicity is not required for LCMV-induced weight loss. A
potential mediator of this chronic wasting disease is tumor
necrosis factor (TNF)-a, which is produced by LCMV-specific
CD41 CTLs. In contrast to LCMV-induced weight loss, lethal
LCM disease in b2m2 mice is dependent on Fas-mediated
cytotoxicity. Transfer of immune splenocytes from LCMV-
infected b2m2mice into irradiated infected b2m2mice results
in death of recipient animals. In contrast, transfer of these
splenocytes into irradiated infected b2m2.lpr mice does not
cause death. Thus a role for CD41 T-cell-mediated cytotox-
icity in virus-induced immunopathology has now been dem-
onstrated.
In recent years considerable advances have been made in our
understanding of the mechanisms of cytotoxic T-lymphocyte
(CTL)-mediated cytotoxicity. Elegant studies using cultured
cell lines and mutant mouse strains have demonstrated that at
least two independent cytotoxic mechanisms can be deployed
by CTLs (1–3). Many CTL have cytoplasmic granules which
contain perforin and granzyme proteases (4). When such
CTLs encounter target cells that display appropriate major
histocompatibility complex (MHC)–peptide complexes, the
granule contents are secreted toward the target cell. The target
cell membrane is permeabilized by perforin, and the subse-
quent uptake of granzymes initiates a cascade of events that
ultimately results in cell death. In addition to this perforin-
dependent pathway, certain T cells can lyse target cells by a
Fas-dependent mechanism (1–3). The interaction between the
Fas molecule (CD95) on target cells and its ligand, FasL, on
activated T cells results in receptor aggregation, which trans-
duces signals leading to apoptosis of the target cell. Thus,
unlike perforin-dependent CTLs, Fas-dependent T cells can
lyse only target cells that express Fas. Although perforin-
dependent and Fas-dependent killing represent the major
pathways of cell-mediated cytotoxicity, other lytic mechanisms
exist. For example, production of either membrane-associated
or secreted tumor necrosis factor (TNF)-a by T cells can
induce apoptosis in certain cell types (5).
CTLs play an important role in the control of intracellular
pathogens and in the elimination of tumorigenic cells (3, 6). In
the case of lymphocytic choriomeningitis (LCM) virus
(LCMV) infection of mice, virus-specific CD81 CTLs are
required for clearance of virus following peripheral infection
and for the development of lethal meningitis following intra-
cranial (i.c.) inoculation (7). Unlike normal mice, mice that
lack perforin fail to control LCMV infection and do not
develop lethal meningitis following i.c. infection, despite hav-
ing high levels of Fas-dependent CD81 CTLs (8, 9). Similar to
CD81 CTLs, both perforin-dependent and Fas-dependent
CD41 CTLs have been described (2, 3, 10). In contrast to
CD81 CTLs, however, the biological role of CD41 T-cell-
mediated cytotoxicity is poorly understood.
To further investigate the role of CD41 CTLs in vivo, we
have studied LCMV infection of b2-microglobulin-deficient
(b2m2) mice. b2m2 mice are unable to express MHC class I
complexes efficiently and, therefore, are deficient in CD81 T
cells (11, 12). We have previously shown that these mice do not
elaborate CD81, MHC class I-restricted, CTLs following
LCMV infection, but instead generate virus-specific, CD41,
MHC class II-restricted CTLs that are detectable directly ex
vivo (13–15). Despite the induction of this alternative subset of
CTLs, b2m2 mice are unable to clear LCMV infection and,
following i.c. inoculation, succumb to a chronic wasting disease
that is dependent on CD41 T cells (13–16). In addition, we
demonstrated, using adoptive transfer experiments, that these
LCMV-induced CD41 T cells can cause lethal disease in
irradiated infected b2m2 recipient mice (13).
In this report, we have defined the cytolytic mechanism used
by LCMV-specific CTLs in b2m2 mice. Furthermore, we have
determined the role of this CD41 T-cell-mediated cytotoxicity
in causing lethal LCM disease in these animals.
MATERIALS AND METHODS
Mice and Virus. The 1293B6.b2m2 mice used in these
investigations have been previously described (13). In certain
experiments C57BLy6J-B2 mtm1 UNC or STOCK B2 mtm1 UNC
were used (The Jackson Laboratory). Fas-deficient b2m2
C57BL6.b2m2.lpr (b2m2.lpr) mice (17) and C57BLy6 (B6)
mice were bred and maintained at the University of North
Carolina. All of these strains of mice are H2b. Male and female
mice between 8 and 15 weeks of age were used.
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The Armstrong-3 strain of LCMV was kindly provided by J.
L. Whitton (Scripps Research Institute, La Jolla, CA). Virus
was propagated in BHK-21 cells and was titered by plaque
assay on Vero cell monolayers. Mice were infected by intra-
peritoneal (i.p.) inoculation with 23 104 plaque-forming units
(pfu) of LCMV or were anesthetized with Metofane (Pitt-
mann-Moore, Mundelein, IL) and inoculated i.c. with 2 3 103
pfu of virus in a volume of 20 ml.
Cell Lines. EL 4 (MHC class I1, class II2; H2b) cells were
cultured in RPMI-1640 medium supplemented with 10%
(volyvol) fetal calf serum (FCS), 2 mM L-glutamine, 10 mM
Hepes, and 50 mM 2-mercaptoethanol. P815 (MHC class I1,
class II2; H2d) and LB 27.4 (MHC class I1, class II1; H2b/d)
cells were cultured in Dulbecco’s modified Eagle’s medium
containing glucose at 4.5 gyliter and supplemented with 10%
FCS, 2 mM L-glutamine, and 50 mM 2-mercaptoethanol. All
cell lines were obtained from the American Type Culture
Collection.
Selection of Anti-Fas-Resistant Cell Lines. LB27.4 cells
(1 3 108) were g-irradiated [450 rad (1 rad 5 0.01 Gy)] in a
GammaCell-40 irradiator and allowed to recover in tissue
culture for 5 days. The apoptosis-inducing anti-Fas antibody
Jo2 (PharMingen) was then added to the culture to give a final
concentration of 2 mgyml. Twelve days later, surviving cells
were cloned by limiting dilution on a feeder layer of g-irradi-
ated (3000 rad) mouse embryonic fibroblasts. The anti-Fas-
resistant phenotype of these clones was maintained by the
periodic addition of Jo2 to the cultures at 1mgyml. One of these
anti-Fas-resistant clones, 3B10, was selected for further study.
Cytotoxicity Assays. LCMV-specific CTL activity was de-
termined by using 5-hr 51Cr release assays as described pre-
viously (14). Effector cells were prepared from the spleens of
i.p. inoculated B6 or b2m2 mice at 7–8 or 10–11 days after
infection, respectively. These time points correspond to the
peak of the LCMV-specific CTL response in the respective
mouse strains (14). For ‘‘cold target’’ inhibition assays, various
numbers of nonradiolabeled competitor cells (‘‘cold targets’’)
were mixed with 2.5 3 105 effector cells. 51Cr-labeled LCMV-
infected LB27.4 cells (5 3 103) were then added to give an
effector-to-labeled-target ratio of 50:1. Following incubation,
supernatants were harvested by using a Skatron harvesting
system (Skatron Instruments, Sterling, VA). The amount of
51Cr released was quantified by g counting, and the percent
specific lysis was calculated as previously described (14). All
assays were performed in triplicate.
To determine if effector cell protein synthesis is required
for CTL activity, effector cells were pretreated with the
irreversible protein synthesis inhibitor emetine (Sigma), for
1 hr at 378C. Treated effector cells were washed three times
prior to use in CTL assays. In certain experiments nylon
wool-purified splenic effector cells were preincubated with 7
mg of Fas-Ig fusion protein (ref. 18; kindly provided by P.
Leder and B. Stanger, Harvard Medical School, Boston) or
with an equivalent concentration of human IgG1 (Sigma) for
30 min at 378C. These effector cells were then used in CTL
assays as described above.
Standard 51Cr-release assays were also used to measure
anti-Fas-induced cytotoxicity. 51Cr-labeled target cells (5 3
103) were added into wells of U-bottom 96-well plates, which
contained either no antibody or the anti-Fas mAb Jo2, to give
a final volume of 200 ml. After incubation for 5 hr at 378C in
a 6% CO2y94% air atmosphere, the supernatants were har-
vested and radioactivity was measured as described above.
TNF-a production by LCMV-specific class II-restricted
CTLs was determined in bystander lysis assays exactly as
described by Hou et al. (19), using the TNF-a-sensitive EL 4
cell line and the TNF-a-resistant P815 cell line (19, 20). The
assays were allowed to proceed for 6 hr at 378C in 6%CO2, and
the supernatants were harvested and radioactivity was mea-
sured as described above. For neutralization of TNF, rabbit
antiserum to murine TNF-a (Genzyme) was added to the wells
to give a final dilution of 1:200.
Flow Cytometry. Staining and analysis of spleen cells were
performed essentially as previously described (14). Briefly,
spleen cells were prepared from untreated b2m2mice or from
b2m2 mice that had been infected i.p with LCMV 10 days
earlier. Erythrocytes were removed by osmotic lysis and Fc
receptors were blocked with mAb 2.4G2 (0.4 mg per 106 cells).
Cells were stained with phycoerythrin (PE)-conjugated anti-
CD4 (RM4-5; 0.5 mg per 106 cells) together with fluorescein
isothiocyanate (FITC)-conjugated anti-CD45RB (16A; 1 mg
per 106 cells) or FITC-conjugated anti-CD49d (9C10; 1 mg
per 106 cells). For analysis of CD44 expression, cells were
stained with FITC-conjugated anti-CD4 (0.5 mg per 106
cells) together with PE-conjugated anti-CD44 (IM7; 1 mg per
106 cells). All antibodies were obtained from PharMingen.
After washing, stained cells were analyzed with a FACScan
f low cytometer (Becton Dickinson), and collected data were
examined using the computer program CICERO (Cytomation,
Fort Collins, CO). Dead cells were excluded on the basis of
forward and side scatter.
Cell surface TNF-a expression on purified CD41 cells was
also determined by flow cytometry (5). Spleen cells were
prepared as described above and CD41 cells were isolated
from these cell suspensions by using anti-CD4-coatedmagnetic
beads (L3T4 microbeads, Miltenyi Biotec, Auburn, CA) in
accordance with the manufacturer’s instructions. The purified
cells were greater than 95% CD41 as assessed by flow cytom-
etry. Cell surface TNF expression was determined by staining
the cells with anti-TNF (MP6-XT3; 1 mg per 106 cells) for 30
min at 48C. Following washing, FITC-conjugated anti-rat IgG1
(RG11y39.4; 1 mg per 106 cells) was added and the cells were
incubated for a further 30 min at 48C. Control samples were
stained with the secondary antibody only. FACScan analysis
was performed as described above.
Adoptive Transfer of Immune Splenocytes. Single-cell sus-
pensions were prepared from the spleens of donor b2m2 mice
that had been infected i.p with LCMV 10–11 days previously.
Erythrocytes were removed by osmotic lysis and the remaining
cells were resuspended in PBS prior to transfer. Aliquots of
these cells (1.7 3 108 or 1.8 3 108) were injected i.p. into
recipient mice that had been irradiated (600 rad) and infected
i.c. with LCMV 5 days previously. Control recipient mice were
irradiated and infected but did not receive donor cells. Mice
were monitored daily for morbidity and mortality.
RESULTS
Anti-Fas-Resistant Cells Are Refractory to Lysis by CD41
CTLs. Following infection with LCMV, b2m2 mice generate
virus-specific CD41 CTLs which are detectable directly ex vivo
(12). Cell lines resistant to anti-Fas-induced cell death were
used to determine if these CTLs use a Fas-dependent lytic
mechanism. Addition of the anti-Fas mAb Jo2 to 51Cr-labeled
LB27.4 cells results in cell death as assessed by 51Cr release
(Fig. 1A) and microscopic examination (data not shown). In
contrast, the 3B10 cell line, derived from LB27.4 by irradiation
mutagenesis and selection using Jo2, is resistant to anti-Fas-
induced cell death (Fig. 1A). Standard 51Cr release assays were
performed to determine if the Jo2-resistant 3B10 cells are
susceptible to lysis by CTLs. Virus-specific CTLs from either
LCMV-infected B6 mice, which generate CD81 perforin-
dependent CTLs (8, 9), or LCMV-infected b2m2 mice, which
elaborate CD41 CTLs, were used as effectors. As expected,
LCMV-infected LB27.4 cells are lysed by effector cells from
both B6 and b2m2mice (Fig. 1B). In contrast, LCMV-infected,
anti-Fas-resistant, 3B10 cells are lysed by effector cells fromB6
mice but are not lysed above background levels by LCMV-
specific CD41 CTLs from b2m2 mice (Fig. 1C).
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The results shown in Fig. 1C demonstrate that LCMV-
infected 3B10 cells are resistant to lysis by virus-specific class
II-restricted CTLs. To determine if 3B10 cells are capable of
presenting LCMV antigen to these CD41 CTLs, unlabeled
target competition assays were performed. Because LCMV-
infected LB27.4 cells are recognized by CTLs, the addition of
excess nonradiolabeled infected LB27.4 cells competitively
inhibits lysis of infected 51Cr-labeled LB27.4 cells (Fig. 1D,
shaded bars). Similarly, the addition of nonradiolabeled
LCMV-infected 3B10 cells also blocks lysis of infected 51Cr-
labeled LB27.4 cells (Fig. 1D, hatched bars). In contrast, the
addition of noninfected LB27.4 or noninfected 3B10 cells does
not markedly inhibit CTL-mediated lysis (Fig. 1D, solid and
open bars, respectively). Since both infected LB27.4 cells and
infected 3B10 cells can block lysis by virus-specific, class
II-restricted CTLs, these data show that both cell types are
capable of being recognized by these CTLs. Taken together,
these data demonstrate that 3B10 cells are not defective in
their ability to be recognized by class II-restricted CTLs, but
they are impaired in their ability to be killed by these CTLs.
Inhibitors of Fas-Dependent Cytotoxicity Block CTL-
Mediated Lysis. We next investigated whether inhibitors of
Fas-dependent CTL activity affected the ability of LCMV-
specific class II-restricted CTLs to lyse target cells. Inhibition
of T-cell protein synthesis prevents the induction of FasL
expression that occurs when a Fas-dependent CTL engages an
appropriate target cell. Consequently, such treatment can
inhibit the killing by Fas-dependent CTLs but not by perforin-
dependent CTLs (5). Treatment of b2m2 class II-restricted
CTLs with the irreversible protein synthesis inhibitor emetine
prior to assay markedly inhibited the ability of these CTLs to
kill virus-infected target cells (Fig. 2A). Treatment with em-
etine had no effect on effector cell viability over the course of
the assay as assessed by trypan blue dye exclusion (data not
shown). These data further suggest that LCMV-specific class
II-restricted CTLs employ a Fas-dependent lytic mechanism.
To confirm that the LCMV-specific CTLs from b2m2 mice
use a Fas-dependent lytic mechanism, we attempted to inhibit
CTL-mediated killing in 51Cr-release assays by the addition of
soluble Fas-Ig fusion proteins (18). As illustrated in Fig. 2B,
the addition of Fas-Ig prevents CTL-mediated target cell
death. In contrast, the addition of control human IgG1 has no
effect on CTL-mediated target cell death (data not shown).
Taken together with the results shown in Fig. 1, these data
demonstrate that LCMV-specific class II-restricted CTLs from
b2m2 mice primarily employ a Fas-dependent lytic mechanism.
b2m2 and b2m2.lpr Mice Lose Weight Following i.c. Infec-
tion with LCMV. CD41 cells are required for the development
of LCMV-induced weight loss in b2m2 mice (12–15). Since
LCMV-specific CD41 CTL exhibit Fas-dependent lytic activ-
ity in vitro, we investigated whether Fas expression is required
for the development of the wasting disease. We previously
reported that Fas-expressing b2m2mice lose a marked amount
of body weight following i.c. infection (12–14). Similarly, i.c
infected b2m2.lpr mice also develop a wasting disease which
closely resembles that observed in Fas-expressing b2m2 mice
(Fig. 3). In addition to weight loss, both strains showed other
signs of illness, including ruffled fur and lethargy, which were
most pronounced 10–15 days after infection. The finding that
b2m2.lpr mice lose weight after i.c. infection with LCMV
indicates that Fas expression, and therefore Fas-dependent
cytotoxicity, is not required for the development of LCMV-
induced wasting disease.
FIG. 2. Inhibitors of Fas-dependent CTL activity prevent cytolysis
by LCMV-specific CD41 CTLs. Effector cells were prepared from
b2m2 mice at 10 days after i.p. infection and tested for their ability to
lyse 51Cr-labeled LB27.4 cells. (A) Effector cells were preincubated in
medium only (●, E) or with 5 mM emetine (Ç) and tested for their
ability to lyse either infected target cells (Ç, ●) or noninfected target
cells (E). (B) In separate experiments effector cells were assayed for
their ability to lyse LCMV-infected target cells in the presence
(hatched bars) or absence (solid bars) of 7 mg of Fas-Ig. Lysis of
noninfected targets in the absence of Fas-Ig is also shown (open bars).
Addition of 7 mg of human IgG1 does not inhibit CTL activity (data
not shown).
FIG. 1. Anti-Fas-resistant cells are refractory to lysis by LCMV-specific CD41 CTLs. (A) LB27.4 cells (solid bars) or anti-Fas-selected 3B10
cells (open bars) were tested in 51Cr release assays for their ability to be killed by Jo2 mAb. (B and C) LB27.4 (B) and 3B10 cells (C) were tested
for their ability to be lysed by splenic effector cells prepared from B6 mice (E, F) or b2m2 mice (M, m) at 7 or 10 days after i.p. infection with
LCMV, respectively. Target cells were either noninfected (E, M) or infected with LCMV 48 hr previously (F, m). (D) Unlabeled target inhibition
assays were performed using effector cells from LCMV-infected b2m2 mice assayed at an effector to 51Cr-labeled target cell ratio of 50:1. The
51Cr-labeled targets (‘‘hot targets’’) were LCMV-infected LB27.4 cells. Unlabeled competitor cells (‘‘cold targets’’) were added to give cold:hot
target ratio of either 25:1 or 50:1. Cold targets were noninfected LB27.4 cells (solid bars), noninfected 3B10 cells (open bars), LCMV-infected
LB27.4 cells (shaded bars) and noninfected 3B10 cells (hatched bars). Percent relative lysis was calculated as follows: 100 3 (% specific lysis in
the presence of cold targetsy% specific lysis in the absence of cold targets).
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LCMV-Specific CD41 CTLs Produce TNF-a. The finding
that LCMV-induced wasting in b2m2 mice is dependent on
CD41 cells but does not require the Fas-dependent cytotoxic
activity prompted us to examine TNF-a production by these
class II-restricted T cells. TNF-a is a potent cachectic cytokine
(21) and, therefore, is a potential mediator of LCMV-induced
weight loss. We stained CD41 cells from LCMV-infected
b2m2 mice with a mAb to detect cell-associated TNF-a, an
indicator of TNF-a production (5). CD41 cells from LCMV-
infected b2m2 mice express increased levels of surface TNF-a
compared with CD41 cells from noninfected b2m2 mice (Fig.
4A). Production of TNF-a was confirmed in bystander lysis
experiments. LCMV-specific CTLs from b2m2 mice were
cultured with either noninfected or LCMV-infected nonradio-
labeled LB27.4 cells. Addition of 51Cr-labeled TNF-a-sensitive
EL 4 cells to cultures containing infected LB27.4 cells resulted
in lysis of the EL 4 cells (Fig. 4B). This bystander lysis of EL
4 cells was inhibited by addition of neutralizing antiserum
against TNF-a. In contrast, TNF-a-resistant P815 cells were
not killed in these bystander lysis experiments. Overall, these
data demonstrate that LCMV-specific class II-restricted T cells
from b2m2 mice produce the cachectic cytokine TNF-a.
Fas Expression Is Required for Adoptive Transfer of Lethal
LCM Disease. The results shown in Fig. 3 demonstrate that
Fas-dependent cytotoxicity is not required for LCMV-induced
weight loss in b2m2 mice. We have previously demonstrated
that adoptively transferred LCMV-specific CD41 cells can
cause lethal disease in irradiated, i.c. infected, recipient b2m2
mice (13). We therefore examined if Fas-dependent cytotox-
icity is necessary for adoptive transfer of lethal LCM disease.
Donor cells were prepared from the spleens of i.p. infected
b2m2 mice 10 days after infection. As shown in Fig. 5,
compared with spleen cells from noninfected mice, the spleens
of infected b2m2 mice contain an increased percentage of
CD41 cells which are CD45RBlow (47.3% compared with 37%),
CD44high (52.9% compared with 31.3%), and CD49dhigh (45.4%
compared with 17.6%). Thus, 10 days after LCMV infection of
b2m2 mice, approximately 50% of splenic CD41 cells have a
phenotype characteristic of activated T cells (22, 23).
These activated spleen cells were injected i.p. into either
irradiated i.c. infected b2m2 mice or irradiated i.c. infected
b2m2.lpr mice. As expected, adoptive transfer of immune
spleen cells into the b2m2 recipients caused lethal LCM
disease (Table 1). In contrast, adoptive transfer of these cells
into b2m2.lpr recipient mice did not result in death of the
recipient animals. Irradiated infected control mice of either
strain that did not receive donor cells did not die. In addition,
we have previously shown that transfer of splenocytes from
noninfected b2m2mice does not cause any disease in recipient
mice (13). These data show that expression of Fas in recipient
b2m2 mice is required for adoptive transfer of lethal LCM
disease.
DISCUSSION
In this report, we have determined the mechanism of cyto-
toxicity of the LCMV-specific CD41 CTLs in b2m2 mice and
have examined the requirement for cytotoxic effector function
in LCM disease. We show that the LCMV-specific, MHC class
II-restricted CTLs in b2m2 mice predominantly use a Fas-
dependent lytic mechanism. Furthermore, we demonstrate
that this Fas-dependent CTL activity is required for causing
lethal LCM disease but is not necessary for causing chronic
wasting following i.c. infection of b2m2 mice with LCMV.
Normal mice elaborate virus-specific, class I-restricted,
CD81 CTLs following infection with LCMV. These antiviral
CTL predominantly exhibit perforin-dependent cytotoxic ac-
tivity (8, 9). b2m2 (H2b) mice are unable to mount a detectable
CD81 antiviral CTL response but instead generate CD41 class
II-restricted CTLs (12–15). CD41 CTLs have also been de-
tected in normal mice after infection with certain viruses or
after immunization with certain antigens. In these instances
the cytotoxic mechanisms used by CD41CTLs have frequently
FIG. 3. b2m2 and b2m2.lpr mice lose weight after i.c. inoculation
with LCMV. b2m2 (m) and b2m2.lpr (M) mice were inoculated i.c. with
23 103 pfu of LCMV.Mice were weighed at regular intervals and their
weights were expressed as percent change from their initial (day 0)
body weights (mean percent change 6 SEM; n 5 4).
FIG. 4. CD41 cells from LCMV-infected b2m2mice produce TNF-a. (A) CD41 cells were isolated from the spleens of noninfected b2m2mice
(histogram 1) or from b2m2 mice that had been infected 10 days previously (i.p.) with LCMV (histograms 2 and 3). Fc receptors were blocked
with mAb 2.4G2, and surface expression of TNF-a was detected by using rat anti-TNF-a followed by FITC-conjugated anti-rat IgG1 (histograms
1 and 3). Control cells from infected mice were stained with FITC-conjugated anti-rat IgG1 only (histogram 1). (B) Production of biologically active
TNF-a by LCMV-specific class II-restricted cells was assessed in bystander lysis assays. Spleen cells from LCMV-infected b2m2mice were cultured
with infected LB27.4 cells and either 51Cr-labeled TNF-a-sensitive EL 4 cells (m) or 51Cr-labeled TNF-a-resistant P815 cells (E) were added.
Bystander lysis of EL 4 cells was blocked by addition of 0.5% (final concentration) of rabbit anti-mouse TNF-a (M). Spleen cells from infected
mice were also cultured with noninfected LB27.4 cells, and bystander lysis of 51Cr-labeled EL 4 cells was tested (Ç).
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been found to be Fas-dependent (24–26). Recent studies,
however, have demonstrated that the acquisition of perforin-
dependent or Fas-dependent lytic mechanisms by either CD41
or CD81 CTLs can be determined by the stimulation condi-
tions used (10, 27, 28). The LCMV-specific CD41CTL activity
in b2m2 mice is detectable directly ex vivo, therefore, the
cytotoxic mechanism used by these CTLs can be studied
without the need for restimulation in vitro. The inability of the
LCMV-specific b2m2 CTLs to kill anti-Fas-resistant target
cells (Fig. 1) and the inhibition of this CTL activity by using
Fas-Ig (Fig. 2) demonstrates that these CTLs use a Fas-
dependent cytotoxic mechanism. This conclusion is supported
by the observation that CTL activity is inhibited following
treatment of the effector cells with emetine (Fig. 2). Expres-
sion of FasL on the surface of T cells requires de novo protein
synthesis (5), therefore, Fas-dependent cytotoxicity is sensitive
to protein synthesis inhibitors such as emetine. Although b2m2
mice elaborate Fas-dependent LCMV-specific CTLs, these
CTLs are unable to clear the infection (12, 14, 15). LCMV can
infect a wide range of cells in vivo; however, Fas-dependent
CTLs can kill only target cells that express the Fas molecule.
Therefore, infected cells that do not express Fas in vivo will not
be directly eliminated by these CTLs. Consequently, such cells
may serve as a reservoir of virus and lead to persistent
infection. The limited tissue distribution of MHC class II
molecules in vivo also restricts the target cell range of these
class II-restricted CTLs; however, even class I-restricted, Fas-
dependent, CD81 CTLs do not clear LCMV infection (8, 9).
These observations emphasize the limited efficacy of Fas-
dependent class II-restricted CTLs in controlling systemic viral
infections.
The elucidation of the cytotoxic mechanism used by the
b2m2 CTLs has enabled us to investigate the role of this
cytotoxic effector function in LCM disease in b2m2 mice.
Following i.c. infection with LCMV, b2m2 mice succumb to a
CD41 T-cell-dependent, chronic wasting disease (12–16). Like
b2m2mice, b2m2.lprmice also develop similar symptoms after
i.c. infection (Fig. 3). Interestingly, i.c infection of perforin-
deficient mice with LCMV also results in a marked loss of body
weight. Since these strains of mice all succumb to wasting
disease which is similar in both severity and kinetics, this
suggests that neither Fas-dependent nor perforin-dependent
cytotoxicity is required for LCMV-induced weight loss. There-
fore, non-cytolytic lymphocyte effector functions are likely to
mediate this disease. The potent cachectic cytokine TNF-a is
a potential mediator of this wasting disease. We have found
that LCMV-specific class II-restricted T cells from b2m2 mice
produce TNF-a in vitro (Fig. 4). Production of TNF-a by such
cells in vivo could result in weight loss. LCMV infection of
b2m2 mice leads to activation of CD41 T cells (Fig. 5),
resulting in increased expression of CD49d on splenic CD41
cells. CD49d plays an important role in directing specific T
cells to sites of viral infection (29). Mild to moderate infiltrates
of mononuclear cells are apparent in the brains of i.c. infected
b2m2 mice (12, 16). In the brain, infiltrating LCMV-specific
CD41 T cells may react against viral antigen presented on class
II molecules, leading to production of TNF-a within the
central nervous system, a situation that results in dramatic
weight loss (21).
Adoptive transfer of spleen cells from LCMV-infected b2m2
mice into irradiated infected b2m2 mice results in death (13).
Similar to the wasting disease described above, lethal disease
is also dependent on CD41 T cells; however, in contrast to
LCMV-induced wasting, lethal LCMdisease is Fas-dependent.
Transfer of spleen cells from LCMV-infected b2m2 mice into
irradiated, infected, Fas-deficient b2m2.lpr mice does not
result in death of the recipients (Table 1). These data are
consistent with our observation that adoptive transfer of




b2m2 b2m2.lpr b2m2 b2m2.lpr
1 3y3 ND 0y3 ND
2 2y2 0y4 0y3 0y3
3 2y2 0y2 0y2 0y2
Total 7y7‡ 0y6‡ 0y8 0y5
Numbers are deathsytotal. ND, not done.
*Recipient mice received 1.7 3 108 (Exp. 1) or 1.8 3 108 (Exps. 2 and
3) donor splenocytes.
†Control recipient mice did not receive donor cells.
‡These two groups are statistically different (P , 0.001, Fisher’s exact
test).
FIG. 5. Activation of splenic CD41 cells after LCMV infection. Two-color flow cytometric analysis of splenocytes from noninfected b2m2mice
(A–C) or from b2m2 mice that had been infected i.p. with LCMV 10 days previously (D–F) was performed. Cells were stained for CD4 and CD44
(A and D), CD45RB (B and D), or CD49d (a4-integrin) (E and F). The percentages of CD41 cells are indicated in the upper two quadrants of
each plot.
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noncytolytic splenic CD41 cells from LCMV-infected B6 mice
into syngeneic b2m2 recipient mice does not cause lethal
disease (13). Furthermore, these data indicate that pathogenic
mechanisms of LCMV-induced wasting disease and of lethal
LCM disease are distinct. A recent study by Hilderman et al.
(30) supports this hypothesis. Using recombinant vaccinia
viruses expressing LCMV proteins, these authors were able to
vaccinate b2m2 mice against lethal disease, but not against
wasting disease. Our results suggest that lethal immunopathol-
ogy in LCMV-infected b2m2 mice requires cytotoxic effector
function but that the chronic wasting disease is independent of
cell-mediated cytotoxicity.
Unlike the biological role of perforin-dependent cytotoxic-
ity, that of Fas-dependent cytotoxicity is unclear. It has been
proposed that the primary function of Fas-mediated cytolysis
may be to maintain immune system homeostasis (23, 31). Thus,
the induction of FasL on responding T cells may result in the
elimination of other activated T cells (18, 31, 32) as well as B
cells (32) and macrophages (33). In contrast, the Fas-
dependent cytotoxic activity we observe in LCMV-infected
b2m2 mice is highly specific. Similar to perforin-dependent
CD81CTLs in normal mice, these Fas-dependent CD41CTLs
mediate antigen-specific MHC-restricted cytolysis in vitro and
cause lethal immunopathology upon adoptive transfer. We
believe, therefore that the induction of Fas-dependent CD41
CTLs in b2m2 mice is an attempt to compensate for the lack
of perforin-dependent CD81 CTLs.
In conclusion, we have demonstrated that LCMV-specific
CD41 CTLs in b2m2 mice utilize a Fas-dependent lytic
mechanism. This cytotoxic activity is not required for the
development of virus-induced chronic wasting disease; how-
ever, adoptive transfer of lethal LCM disease is Fas-
dependent. These data provide the first demonstration, to our
knowledge, of a role for Fas-dependent CD41 CTLs in virus-
induced immunopathology.
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